Pure BiologicsSTU:PQB +0.73%19 Days Payable is 38,644.38 as of Mar. 2026, which is 8439% above its 10-year median of 452.58. GuruFocus rates STU:PQB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Pure Biologics ranks better than 97.29% on this metric.
The historical rank and industry rank for Pure Biologics's Days Payable or its related term are showing as below:
STU:PQB'
s Days Payable Range Over the Past 10 Years
Min: 121.22 Med: 452.58 Max: 25996.81
Current: 25538.32
During the past 10 years, Pure Biologics's highest Days Payable was 25996.81. The lowest was 121.22. And the median was 452.58.
STU:PQB's Days Payable is ranked better than 97.29% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs STU:PQB: 25538.32
Pure Biologics's Days Payable
increased
from Mar. 2025 (17,611.25) to Mar. 2026 (38,644.38).
It may suggest that Pure Biologicsdelayed paying its suppliers.
Pure Biologics Days Payable Related Terms
Pure Biologics Days Payable Historical Data
* Premium members only.
The historical data trend for Pure Biologics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PQB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Pure Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pure Biologics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pure Biologics's Days Payable distribution charts can be found below:
* The bar in red indicates where Pure Biologics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pure Biologics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pure Biologics (STU:PQB) has a Days Payable of 38,644.38 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pure Biologics and its competitors. This is 8439% above median its historical median of 452.58. Over the past decade, Pure Biologics' Days Payable has ranged from 121.22 to 25,996.81. According to the industry distribution chart, Pure Biologics ranks #19 out of 702 companies in the Biotechnology industry, placing it in the top 2.7%.
Is Pure Biologics' Days Payable too high?
Pure Biologics' current Days Payable of 38,644.38 is 8439% above median its 10-year median of 452.58. Over the past 10 years, this metric has ranged from a low of 121.22 to a high of 25,996.81. The Biotechnology industry median Days Payable is 113.10. Pure Biologics' value of 38,644.38 is 34068.3% above this industry median. Based on the distribution chart, Pure Biologics ranks #19 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pure Biologics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pure Biologics ranks #19 out of 702 companies for Days Payable. This places Pure Biologics in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Pure Biologics' value of 38,644.38 is 34068.3% above this benchmark. Historically, Pure Biologics' own Days Payable has ranged from 121.22 to 25,996.81 over the past decade. While the company's 10-year median is 452.58 vs. the industry median of 113.10, Pure Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pure Biologics's current Days Payable of 38,644.38 is 34068.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pure Biologics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pure Biologics's current Days Payable is 38,644.38, which is 8439% above median its own 10-year median of 452.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (STU:PQB) has a current Days Payable of 38,644.38. The current Days Payable is 38,644.38, which is 8439% above median its 10-year median of 452.58 and 34068.3% above the Biotechnology industry median of 113.10. Pure Biologics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pure Biologics (STU:PQB), the current Days Payable is 38,644.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
19GF Score
Get the complete analysis for STU:PQB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PQB has been successfully added to your 
